Beta2-microglobulin adsorption column reduces digoxin trough level during hemodialysis: three case reports

Area of Science:

• Nephrology
• Pharmacology
• Cardiology

Background:

• Dialysis-related amyloidosis (DRA) is a complication in patients with renal failure undergoing hemodialysis.
• Beta2-microglobulin adsorption columns are used to treat DRA by removing beta2-microglobulin.
• Previous studies indicated that these columns can reduce serum digoxin concentrations.

Observation:

• Three renal failure patients treated with tandem beta2-microglobulin adsorption columns for DRA showed reduced trough serum digoxin concentrations.
• These patients experienced increased heart rates correlating with decreased digoxin levels.
• One patient's symptoms improved upon discontinuation of the column, but DRA relapsed.

Findings:

• Repetitive use of beta2-microglobulin adsorption columns in conjunction with hemodialysis significantly decreases trough serum digoxin concentrations in renal failure patients.
• The reduction in digoxin levels can lead to diminished therapeutic effect, evidenced by elevated heart rates.
• Adjusting digoxin dosage upwards was effective in restoring therapeutic levels and heart rate control during column treatment.

Implications:

• Healthcare providers must carefully monitor serum digoxin concentrations in renal failure patients undergoing treatment with beta2-microglobulin adsorption columns.
• Digoxin dosage regimens may require upward adjustments to maintain therapeutic efficacy.
• This highlights the importance of personalized pharmacotherapy in patients with complex conditions like DRA and renal failure.